Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125572291 | 12557229 | 1 | I | 20160705 | 20160714 | 20160714 | EXP | CA-CELGENEUS-CAN-2016071122 | CELGENE | 60.00 | YR | F | Y | 0.00000 | 20160714 | OT | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125572291 | 12557229 | 1 | PS | POMALYST | POMALIDOMIDE | 1 | Oral | 3 MILLIGRAM | U | U | 204026 | 3 | MG | CAPSULES | QD | ||||
| 125572291 | 12557229 | 2 | SS | REVLIMID | LENALIDOMIDE | 1 | Oral | U | U | 21880 | CAPSULES | ||||||||
| 125572291 | 12557229 | 3 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Unknown | U | U | 0 | 40 | MG | UNKNOWN | QD | |||||
| 125572291 | 12557229 | 4 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Oral | 40 MILLIGRAM | U | U | 0 | UNKNOWN | /wk | ||||||
| 125572291 | 12557229 | 5 | SS | VELCADE | BORTEZOMIB | 1 | Intravenous drip | U | U | 66188 | 1.5 | MG/M**2 | SOLUTION | /wk | |||||
| 125572291 | 12557229 | 6 | C | ACYCLOVIR. | ACYCLOVIR | 1 | Oral | 1.5 MILLIGRAM/SQ. METER | 0 | 400 | MG | UNKNOWN | BID | ||||||
| 125572291 | 12557229 | 7 | C | ARANESP | DARBEPOETIN ALFA | 1 | Subcutaneous | 0 | 500 | UG | INJECTION | ||||||||
| 125572291 | 12557229 | 8 | C | Filgrastim | FILGRASTIM | 1 | Subcutaneous | 0 | 300 | UG | INJECTION | /wk | |||||||
| 125572291 | 12557229 | 9 | C | Filgrastim | FILGRASTIM | 1 | Subcutaneous | 0 | 200 | UG | INJECTION | BIW | |||||||
| 125572291 | 12557229 | 10 | C | Pantoprazole | PANTOPRAZOLE SODIUM | 1 | Oral | 0 | 40 | MG | UNKNOWN | QD | |||||||
| 125572291 | 12557229 | 11 | C | Plerixafor | PLERIXAFOR | 1 | Unknown | 0 | UNKNOWN | ||||||||||
| 125572291 | 12557229 | 12 | C | SEPTRA | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | Oral | 800 MILLIGRAM | 0 | TABLETS | QD | ||||||||
| 125572291 | 12557229 | 13 | C | Tenofovir | TENOFOVIR | 1 | Oral | 500 MICROGRAM | 0 | 300 | MG | UNKNOWN | QOD | ||||||
| 125572291 | 12557229 | 14 | C | ZOFRAN | ONDANSETRON HYDROCHLORIDE | 1 | Unknown | 0 | UNKNOWN |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125572291 | 12557229 | 1 | Plasma cell myeloma |
| 125572291 | 12557229 | 2 | Plasma cell myeloma |
| 125572291 | 12557229 | 3 | Plasma cell myeloma |
| 125572291 | 12557229 | 4 | Plasma cell myeloma |
| 125572291 | 12557229 | 5 | Plasma cell myeloma |
| 125572291 | 12557229 | 6 | Product used for unknown indication |
| 125572291 | 12557229 | 7 | Product used for unknown indication |
| 125572291 | 12557229 | 8 | Product used for unknown indication |
| 125572291 | 12557229 | 10 | Product used for unknown indication |
| 125572291 | 12557229 | 11 | Haematopoietic stem cell mobilisation |
| 125572291 | 12557229 | 12 | Product used for unknown indication |
| 125572291 | 12557229 | 13 | Product used for unknown indication |
| 125572291 | 12557229 | 14 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125572291 | 12557229 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125572291 | 12557229 | Epistaxis | |
| 125572291 | 12557229 | Infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |